Drug intelligence / Profile preview

BP51

Development stage: Preclinical
Lead developer: CuraTeQ Biologics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

BP51 is a biosimilar candidate of guselkumab (Tremfya), a selective interleukin-23 (IL-23) inhibitor. Developed by CuraTeQ Biologics (a subsidiary of Aurobindo Pharma), BP51 is currently in preclinical and CMC development. It is being developed for the treatment of immunological and inflammatory diseases, including plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.

Targets

IL23A (Interleukin-23 p19 Subunit)

Beyond the preview

Go deeper on BP51.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BP51.